Abstract
The risk of invasive aspergillosis (IA) is considered to be low among autologous HSCT recipients, but an increase in the incidence has been observed recently in this setting. The aim of the study was to assess the influence of immunosuppressive drugs (steroids, rituximab, fludarabine, thalidomide), used in treatment of lymphoid malignancies during 6 months of pretransplant period, on IA incidence after autologous HSCT. A total of 109 patients with non-Hodgkin's lymphoma (NHL), Hodgkin's disease (HD) and multiple myeloma (MM), conditioned with carmustine, etoposide, cytarabine, melphalan or melphalan and transplanted with PBSC, were analyzed prospectively. Patients were monitored with twice-weekly galactomannan test. High-resolution computed tomograhy of the chest and bronchoscopy were performed in case of positive galactomanan test, persistent fever or pulmonary infiltrates. Documented IA was diagnosed in nine (8%) patients (three proven, six probable). The incidence of IA was comparable in NHL, HD and MM patients and not influenced by age, advanced disease or conditioning regimen. Factors significant for development of documented IA by univariate analysis were treatment with fludarabine (P=0.008) or rituximab (P=0.039). The only factor predicting documented IA by multivariate analysis was treatment with fludarabine (P=0.008). Patients treated with fludarabine or rituximab in pretransplant period are at risk of IA and require close monitoring and/or anti-mould prophylaxis.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Marr KA, Carter RA, Crippa F, Wald A, Corey L . Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis 2002; 34: 909–917.
Lin SJ, Schranz J, Teutsch SM . Aspergillosis case-fatality rate: systematic review of the literature. Clin Infect Dis 2001; 32: 358–366.
Marr KA, Carter RA, Boeckh M, Martin P, Corey L . Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors. Blood 2002; 100: 4358–4366.
Gil L, Styczynski J, Komarnicki M . Infectious complication in 314 patients after high-dose therapy and autologous hematopoietic stem cell transplantation: risk factors analysis and outcome. Infection 2007; 35: 421–427.
Mennink-Kersten MA, Donnelly JP, Verweij PE . Detection of circulating galactomannan for the diagnosis and management of invasive aspergillosis. Lancet Infect Dis 2004; 4: 349–357.
Kedzierska A, Kochan P, Pietrzyk A, Kedzierska J . Current status of fungal cell wall components in the immunodiagnostics of invasive fungal infections in humans: galactomannan, mannan and (1 → 3)-beta-D-glucan antigens. Eur J Clin Microbiol Infect Dis 2007; 26: 755–766.
Ascioglu S, Rex JH, de Pauw B, Bennett JE, Bille J, Crokaert F et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 2002; 34: 7–14.
Hughes WT, Armstrong D, Bodey GP, Bow EJ, Brown AE, Calandra T et al. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 2002; 34: 730–751.
Maertens J, Theunissen K, Verhoef G, Verschakelen J, Lagrou K, Verbeken E et al. Galactomannan and computed tomography-based preemptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection: a prospective feasibility study. Clin Infect Dis 2005; 41: 1242–1250.
Chamilos G, Luna M, Lewis RE, Bodey GP, Chemaly R, Tarrand JJ et al. Invasive fungal infections in patients with hematologic malignancies in a tertiary care cancer center: an autopsy study over a 15-year period (1989–2003). Haematologica 2006; 91: 986–989.
Cornillet A, Camus C, Nimubona S, Gandemer V, Tattevin P, Belleguic C et al. Comparison of epidemiological, clinical, and biological features of invasive aspergillosis in neutropenic and nonneutropenic patients: a 6-year survey. Clin Infect Dis 2006; 43: 577–584.
Viscoli C, Machetti M, Cappellano P, Bucci B, Bruzzi P, Van Lint MT et al. False-positive galactomannan platelia Aspergillus test results for patients receiving piperacillin-tazobactam. Clin Infect Dis 2004; 38: 913–916.
Cornet M, Fleury L, Maslo C, Bernard JF, Brucker G . Epidemiology of invasive aspergillosis in France: a six-year multicentric survey in the Greater Paris area. J Hosp Infect 2002; 51: 288–296.
Caillot D, Casasnovas O, Bernard A, Couaillier JF, Durand C, Cuisenier B et al. Improved management of invasive pulmonary aspergillosis in neutropenic patients using early thoracic computed tomographic scan and surgery. J Clin Oncol 1997; 15: 139–147.
Maertens J, Verhaegen J, Lagrou K, Van Eldere J, Boogaerts M . Screening for circulating galactomannan as a noninvasive diagnostic tool for invasive aspergillosis in prolonged neutropenic patients and stem cell transplantation recipients: a prospective validation. Blood 2001; 97: 1604–1610.
Muhlemann K, Wenger C, Zenhausern R, Tauber MG . Risk factors for invasive aspergillosis in neutropenic patients with hematologic malignancies. Leukemia 2005; 19: 545–550.
Lionakis MS, Kontoyiannis DP . Glucocorticoids and invasive fungal infections. Lancet 2003; 362: 1828–1838.
Lortholary O, Ascioglu S, Moreau P, Herbrecht R, Marinus A, Casassus P et al. Invasive aspergillosis as an opportunistic infection in nonallografted patients with multiple myeloma: a European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the Intergroupe Francais du Myelome. Clin Infect Dis 2000; 30: 41–46.
Ketterer N, Espinouse D, Chomarat M, Dumontet C, Moullet I, Rieux C et al. Infections following peripheral blood progenitor cell transplantation for lymphoproliferative malignancies: etiology and potential risk factors. Am J Med 1999; 106: 191–197.
Jantunen E, Itala M, Lehtinen T, Kuittinen O, Koivunen E, Leppa S et al. Early treatment-related mortality in adult autologous stem cell transplant recipients: a nation-wide survey of 1482 transplanted patients. Eur J Haematol 2006; 76: 245–250.
Cohen BJ, Moskowitz C, Straus D, Noy A, Hedrick E, Zelenetz A . Cyclophosphamide/fludarabine (CF) is active in the treatment of mantle cell lymphoma. Leuk Lymphoma 2001; 42: 1015–1022.
Bosch F, Ferrer A, Lopez-Guillermo A, Gine E, Bellosillo B, Villamor N et al. Fludarabine, cyclophosphamide and mitoxantrone in the treatment of resistant or relapsed chronic lymphocytic leukaemia. Br J Haematol 2002; 119: 976–984.
McLaughlin P, Hagemeister FB, Romaguera JE, Sarris AH, Pate O, Younes A et al. Fludarabine, mitoxantrone, and dexamethasone: an effective new regimen for indolent lymphoma. J Clin Oncol 1996; 14: 1262–1268.
O'Brien SM, Kantarjian HM, Cortes J, Beran M, Koller CA, Giles FJ et al. Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia. J Clin Oncol 2001; 19: 1414–1420.
Frank DA, Mahajan S, Ritz J . Fludarabine-induced immunosuppression is associated with inhibition of STAT1 signaling. Nat Med 1999; 5: 444–447.
Cabanillas F, Liboy I, Pavia O, Rivera E . High incidence of non-neutropenic infections induced by rituximab plus fludarabine and associated with hypogammaglobulinemia: a frequently unrecognized and easily treatable complication. Ann Oncol 2006; 17: 1424–1427.
Tam CS, Wolf MM, Januszewicz EH, Grigg AP, Prince HM, Westerman D et al. A new model for predicting infectious complications during fludarabine-based combination chemotherapy among patients with indolent lymphoid malignancies. Cancer 2004; 101: 2042–2049.
McLaughlin P, Grillo-Lopez AJ, Link BK, Levy R, Czuczman MS, Williams ME et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998; 16: 2825–2833.
Kaplan LD, Lee JY, Ambinder RF, Sparano JA, Cesarman E, Chadburn A et al. Rituximab does not improve clinical outcome in a randomized phase 3 trial of CHOP with or without rituximab in patients with HIV-associated non-Hodgkin lymphoma: AIDS-Malignancies Consortium Trial 010. Blood 2005; 106: 1538–1543.
Shlomchik MJ, Craft JE, Mamula MJ . From T to B and back again: positive feedback in systemic autoimmune disease. Nat Rev Immunol 2001; 1: 147–153.
Imashuku S, Teramura T, Morimoto A, Naya M, Kuroda H . Prolonged hypogammaglobulinemia following rituximab treatment for post transplant Epstein-Barr virus-associated lymphoproliferative disease. Bone Marrow Transplant 2004; 33: 129–130.
Schutt P, Brandhorst D, Stellberg W, Poser M, Ebeling P, Muller S et al. Immune parameters in multiple myeloma patients: influence of treatment and correlation with opportunistic infections. Leuk Lymphoma 2006; 47: 1570–1582.
Auner HW, Sill H, Mulabecirovic A, Linkesch W, Krause R . Infectious complications after autologous hematopoietic stem cell transplantation: comparison of patients with acute myeloid leukemia, malignant lymphoma, and multiple myeloma. Ann Hematol 2002; 81: 374–377.
Reich G, Mapara MY, Reichardt P, Dorken B, Maschmeyer G . Infectious complications after high-dose chemotherapy and autologous stem cell transplantation: comparison between patients with lymphoma or multiple myeloma and patients with solid tumors. Bone Marrow Transplant 2001; 27: 525–529.
Salazar R, Sola C, Maroto P, Tabernero JM, Brunet J, Verger G et al. Infectious complications in 126 patients treated with high-dose chemotherapy and autologous peripheral blood stem cell transplantation. Bone Marrow Transplant 1999; 23: 27–33.
Jantunen E, Salonen J, Juvonen E, Koivunen E, Siitonen T, Lehtinen T et al. Invasive fungal infections in autologous stem cell transplant recipients: a nation-wide study of 1188 transplanted patients. Eur J Haematol 2004; 73: 174–178.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Gil, L., Kozlowska-Skrzypczak, M., Mol, A. et al. Increased risk for invasive aspergillosis in patients with lymphoproliferative diseases after autologous hematopoietic SCT. Bone Marrow Transplant 43, 121–126 (2009). https://doi.org/10.1038/bmt.2008.303
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/bmt.2008.303
Keywords
This article is cited by
-
Age difference of patients with and without invasive aspergillosis: a systematic review and meta-analysis
BMC Infectious Diseases (2024)
-
Invasive Mold Infections in Patients with Chronic Lymphoproliferative Disorders
Current Fungal Infection Reports (2018)
-
Epidemiology and treatment of invasive fungal diseases in patients with multiple myeloma: findings from a multicenter prospective study from China
Tumor Biology (2016)
-
The protective role of immunoglobulins in fungal infections and inflammation
Seminars in Immunopathology (2015)
-
The risk of infections in hematologic patients treated with rituximab is not influenced by cumulative rituximab dosage - a single center experience
BMC Infectious Diseases (2014)